Dendreon (DNDN): Brean Murray Says Crossover Trial Design Confounds Survival Analysis
Tweet Send to a Friend
Brean Murray comments on Dendreon Corp. (Nasdaq: DNDN). The firm said, "Crossover trials confound analysis of survival. The SPARC ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
